RECURRENT OVARIAN CANCER
Clinical trials for RECURRENT OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OVARIAN CANCER trials appear
Sign up with your email to follow new studies for RECURRENT OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Ancient herb meets modern medicine: ashwagandha trial for ovarian cancer
Disease control Recruiting nowThis study tests whether adding Ashwagandha (an herbal supplement) to standard chemotherapy (DOXIL) is safe and effective for people with ovarian cancer that has returned after initial treatment. About 72 participants will first help find the best Ashwagandha dose, then researche…
Matched conditions: RECURRENT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Sham Sunder Kakar • Aim: Disease control
Last updated May 17, 2026 05:46 UTC
-
New hope for hard-to-treat ovarian cancer: experimental combo enters human trial
Disease control Recruiting nowThis study tests whether adding an experimental drug called CapsuleX to standard cisplatin chemotherapy can shrink tumors in people with ovarian cancer that no longer responds to platinum-based drugs. About 40 adults with recurrent ovarian, fallopian tube, or primary peritoneal c…
Matched conditions: RECURRENT OVARIAN CANCER
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 17, 2026 05:32 UTC
-
New antibody combo shows promise for Tough-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests an experimental drug called ubamatamab, given alone or with another drug (cemiplimab), for people with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back. The main goals are to check safety, find the best dose, and see if the drugs can …
Matched conditions: RECURRENT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
Can eye drops prevent vision problems in ovarian cancer treatment?
Symptom relief Recruiting nowThis study looks at how to reduce eye problems caused by the drug mirvetuximab soravtansine in people with recurrent ovarian cancer. About 100 participants will receive the drug and be monitored for eye side effects, with some using special eye drops to try to prevent them. The g…
Matched conditions: RECURRENT OVARIAN CANCER
Phase: PHASE2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated May 11, 2026 20:46 UTC